Amid CEO turmoil, Allarity loses rights to Novartis cancer drug over missed payments

Already reeling from the controversial termination of its CEO, Allarity Therapeutics has now been told that Novartis is rescinding the rights to a troubled cancer drug after the biotech failed to keep up with its payments.